NCT01315132 2026-03-19
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
Clinical Trials
210 trialsNCT02405676 2026-03-19
BNHL-2015
Children's Cancer Group, China
Phase 2/3 Active not recruiting
NCT03502733 2026-03-19
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04439201 2026-03-19
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439318 2026-03-19
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT06303167 2026-03-19
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06385483 2026-03-19
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400238 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04301076 2026-03-18
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04439292 2026-03-18
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439331 2026-03-18
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439357 2026-03-18
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05490771 2026-03-18
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06308822 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390826 2026-03-17
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390839 2026-03-17
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06859424 2026-03-17
ACCELERATE
Center for International Blood and Marrow Transplant Research
Phase 2 Recruiting
NCT07476378 2026-03-17
Archonc-001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT02332668 2026-03-16
MK-3475-051
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT05131022 2026-03-16
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT05294367 2026-03-16
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT07137494 2026-03-16
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07221500 2026-03-16
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Phase 2 Recruiting
NCT07472972 2026-03-16
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
University of Zurich
Recruiting
NCT02808780 2026-03-13
OPAL
Janssen Biotech, Inc.
Active not recruiting
NCT05683171 2026-03-13
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06510309 2026-03-13
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06510361 2026-03-13
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06875063 2026-03-13
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
The First Affiliated Hospital of Xiamen University
Phase 1 Recruiting
NCT07128641 2026-03-13
Odronextamab in Low Tumor Volume Advanced FL
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT03223610 2026-03-12
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05332054 2026-03-12
LTFS
Caribou Biosciences, Inc.
Enrolling by invitation
NCT05442515 2026-03-12
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07284433 2026-03-12
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07465835 2026-03-12
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Electra Therapeutics Inc.
Phase 1 Recruiting
NCT00923507 2026-03-11
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01563874 2026-03-11
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins
National Institutes of Health Clinical Center (CC)
Completed
NCT07015242 2026-03-11
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT04478318 2026-03-10
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
Phase NA Active not recruiting
NCT06645093 2026-03-10
FasteStudien
University of Oslo
Phase NA Enrolling by invitation
NCT05237986 2026-03-09
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06049134 2026-03-09
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT06856226 2026-03-09
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00039676 2026-03-06
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting